Press release
30 May 2017
Immunicums the CEO presents the company at the conferences in June
Immunicum AB
(publ; First North Premier: IMMU.ST), a biotechnology company that develops new immunaktiverande cancer treatments for a number of solid tumors, announced today that Carlos de Sousa, CEO of Immunicum, has been invited to present the company at a number of conferences in June and has also been asked to participate in a panel entitled “New Frontiers in Oncology.” In addition, the company will participate in the 2017 BIO International Convention.
Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum
Date: June 2, 2017
Time for Immunicums presentation: 11:10 CST
Location: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois
Labiotech Refresh
Date: June 8, 2017
Panel discussion: “New Frontiers in Oncology” 10:30 CET
Location: Spreewerkstätten, Berlin, Germany
Småbolagsdagen
Date: June 12, 2017
Time for Immunicums presentation: 9:20 – 9:50 CET
Location: Sheraton Hotel Stockholm, Stockholm, Sweden
For those who can not attend so the presentation will from Småbolagsdagen be available afterwards on the Immunicums website and can also be followed live on the www.smabolagsdagen.net.
2017 BIO International Convention
(only participants)
Dates: 19-22 June, 2017
Location: San Diego Convention Center, San Diego, California
For further information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor Relations, Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se
Investor relations and media contact, EUROPE/USA
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com
The company’s Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
